From Our Partners
Monday, July 4, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

SIGA Begins Smallpox Drug Shipments to National Stockpile

by Global Biodefense Staff
March 13, 2013

Smallpox Virus Cluster (CDC)SIGA Technologies this week announced the first of a series of deliveries of its proprietary smallpox antiviral drug, Arestvyr (formerly ST-246) to the Strategic National Stockpile under a contract award by the Biomedical Advanced Research and Development Authority (BARDA).

The delivery reignited controversy over the scope and cost of the drug program, with the New York Times reporting the government is paying more than $200 for each course of treatment. The company defended the pricing as a fair and reasonable return on investment, and a bargain compared to prices charged for some patented drugs such as $20,000 a year for AIDS antiretrovirals or cancer drugs costing more than $100,000 a year.

In 2011, BARDA awarded SIGA the base contract for this initial procurement of 1.7 million treatment courses of ST- 246 (Arestvyr). The five-year award was valued at $433 million, of which approximately $412.5 million is for purchase of the drug. 

The order quantity was based on the amount analysts predicted would be needed to contain a smallpox outbreak in a large city. Asked about the scope of the purchase, SIGA president Dr. Eric A. Rose compared it to an influenza drug. “There are 80 million courses of Tamiflu in the strategic national stockpile,” he said. “Smallpox is just as contagious and has 30 times the mortality. By measures like that, I’d say 2 million is on the low end.”

In the summer of 2012, SIGA was ordered by a Delaware court to share profits from the smallpox drug sales with PharmAthene, Inc. The decision followed 5 years of litigation resulting from a failed merger agreement between the companies.

The court entitled PharmAthene to 50% of the net profits over 10 years from all sales of SIGA Technologies’ novel smallpox antiviral. The profit sharing kicks in once SIGA receives the first $40 million in net profits from sales of ST-246.

Read the New York Times article: Wary of Attack With Smallpox, U.S. Buys Up a Costly Drug.

From Our Partners
Tags: AntiviralsASPRBARDABioterrorismHHSRicinSmallpoxStrategic National Stockpile

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC